دورية أكاديمية
أعرض في EDS

Anti-Inflammatory Effects of Huangqin Decoction on Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice Through Regulation of the Gut Microbiota and Suppression of the Ras-PI3K-Akt-HIF-1α and NF-κB Pathways.

التفاصيل البيبلوغرافية
العنوان: Anti-Inflammatory Effects of Huangqin Decoction on Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice Through Regulation of the Gut Microbiota and Suppression of the Ras-PI3K-Akt-HIF-1α and NF-κB Pathways.
المؤلفون: Li MY; Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China., Luo HJ; Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China., Wu X; Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China., Liu YH; Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China., Gan YX; Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China., Xu N; Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China., Zhang YM; Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.; Dongguan Songshan Lake Yidao TCM Clinic, Dongguan, China., Zhang SH; Graduate School, Guangdong Medical University, Dongguan, China., Zhou CL; Graduate School, Guangdong Medical University, Dongguan, China., Su ZR; Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China., Huang XQ; Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China., Zheng XB; Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.; Dongguan Songshan Lake Yidao TCM Clinic, Dongguan, China.
المصدر: Frontiers in pharmacology [Front Pharmacol] 2020 Jan 20; Vol. 10, pp. 1552. Date of Electronic Publication: 2020 Jan 20 (Print Publication: 2019).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Media]
مستخلص: Objective: Huangqin decoction (HQD), a classical traditional Chinese medicinal formula, has been commonly used to treat gastrointestinal diseases for thousands of years. We investigated the anti-inflammatory effects and underlying mechanisms of HQD on dextran sulfate sodium (DSS)-induced ulcerative colitis (UC).
Methods: Experimental mice were given 3% DSS, and HQD (2.275, 4.55, and 9.1 g/kg), or mesalazine (ME, 200 mg/kg) orally for 7 days. Body weight loss, disease activity index (DAI), colon length, histology, and levels of inflammatory cytokines were measured to evaluate the effects of HQD on colitis. The effects of HQD on the Ras-phosphoinositide-3-kinase (PI3K)-Akt-hypoxia inducible factor 1 alpha (HIF-1α) and nuclear factor-kappa B (NF-κB) pathways were evaluated by Western blot analysis. In addition, the gut microbiota was characterized using high-throughput Illumina MiSeq sequencing.
Results: The results showed that HQD significantly reduced the body weight loss, ameliorated DAI, restored colon length, and improved the intestinal epithelial cell barrier in mice with DSS-induced colitis. The messenger RNA (mRNA) expression levels of inflammatory mediators were decreased following HQD treatment. Furthermore, the Ras-PI3K-Akt-HIF-1α and NF-κB pathways were significantly inhibited by HQD. Finally, treatment with HQD resulted in recovery of gut microbiota diversity.
Conclusions: HQD ameliorates DSS-induced colitis through regulation of the gut microbiota, and suppression of Ras-PI3K-Akt-HIF-1α and NF-κB pathways. Our results suggested that HQD may be a potential candidate for treatment of UC.
(Copyright © 2020 Li, Luo, Wu, Liu, Gan, Xu, Zhang, Zhang, Zhou, Su, Huang and Zheng.)
References: J Ethnopharmacol. 2012 Apr 10;140(3):614-23. (PMID: 22326673)
Pharmacol Res. 2016 Aug;110:227-239. (PMID: 26969793)
Curr Opin Pharmacol. 2012 Aug;12(4):458-63. (PMID: 22401931)
J Infect Chemother. 2015 Nov;21(11):761-8. (PMID: 26346678)
Inflamm Bowel Dis. 2009 Mar;15(3):341-52. (PMID: 18942757)
Int Immunopharmacol. 2014 Jun;20(2):337-45. (PMID: 24704625)
Int J Cancer. 2009 Dec 15;125(12):2863-70. (PMID: 19609947)
Oncotarget. 2016 Sep 20;7(38):61643-61655. (PMID: 27557503)
Am J Gastroenterol. 2010 Mar;105(3):501-23; quiz 524. (PMID: 20068560)
Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):9-21. (PMID: 27848962)
Sci Rep. 2017 Oct 2;7(1):12552. (PMID: 28970547)
Curr Gastroenterol Rep. 2010 Oct;12(5):319-30. (PMID: 20703838)
Clin Exp Immunol. 2000 Apr;120(1):51-8. (PMID: 10759763)
ACS Chem Neurosci. 2019 May 15;10(5):2434-2449. (PMID: 30839193)
Annu Rev Cell Dev Biol. 2006;22:409-37. (PMID: 16822173)
Sci Rep. 2017 Sep 25;7(1):12227. (PMID: 28947785)
Gut Microbes. 2019 Mar 26;:1-20. (PMID: 30913966)
Oncotarget. 2017 Jul 25;8(30):48863-48874. (PMID: 28415628)
Biosci Rep. 2018 Nov 28;38(6):. (PMID: 30393231)
J Ethnopharmacol. 2015 Mar 13;162:207-14. (PMID: 25576893)
Biochem Pharmacol. 2018 Feb;148:1-12. (PMID: 29241811)
Curr Gastroenterol Rep. 2004 Dec;6(6):488-95. (PMID: 15527679)
Nat Protoc. 2007;2(3):541-6. (PMID: 17406617)
Biochem Pharmacol. 2005 Nov 1;70(9):1352-60. (PMID: 16169526)
Sci Rep. 2016 Dec 16;6:39299. (PMID: 27982094)
Med Oncol. 2018 Aug 4;35(9):122. (PMID: 30078108)
Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:1-5. (PMID: 12950413)
J Immunol. 2015 Feb 15;194(4):1882-93. (PMID: 25601921)
Trends Immunol. 2012 Mar;33(3):119-26. (PMID: 22277903)
Food Chem Toxicol. 2016 Nov;97:11-22. (PMID: 27546299)
Dis Colon Rectum. 2003 Nov;46(11):1498-507. (PMID: 14605569)
Biochem Pharmacol. 2015 Mar 15;94(2):142-54. (PMID: 25677765)
Clin Dev Immunol. 2012;2012:948098. (PMID: 22778768)
J Leukoc Biol. 2012 Oct;92(4):753-64. (PMID: 22782966)
J Gastroenterol. 2017 Jan;52(1):1-8. (PMID: 27448578)
J Mol Med (Berl). 2011 Feb;89(2):91-4. (PMID: 21161499)
Life Sci. 2017 Oct 1;186:125-132. (PMID: 28802904)
Dig Liver Dis. 2017 Nov;49(11):1171-1176. (PMID: 28988727)
Curr Biol. 2016 Nov 21;26(22):2992-3003. (PMID: 27773571)
J Biol Chem. 2007 Jul 13;282(28):20534-43. (PMID: 17502379)
Cancer Res. 2001 Mar 15;61(6):2641-8. (PMID: 11289142)
EMBO J. 2012 Jul 18;31(14):3118-29. (PMID: 22728827)
Int J Biol Sci. 2018 Nov 3;14(14):2051-2064. (PMID: 30585268)
Nature. 1998 Jan 1;391(6662):86-9. (PMID: 9422510)
Int Immunopharmacol. 2009 Nov;9(12):1444-51. (PMID: 19733697)
Curr Treat Options Oncol. 2014 Sep;15(3):405-20. (PMID: 24792017)
Food Funct. 2016 Jul 13;7(7):3224-32. (PMID: 27334000)
Nat Rev Mol Cell Biol. 2014 Jan;15(1):19-33. (PMID: 24326621)
فهرسة مساهمة: Keywords: Huangqin decoction; NF-κB pathway; Ras-PI3K-Akt-HIF-1α pathway; gut microbiota; ulcerative colitis
تواريخ الأحداث: Date Created: 20200211 Latest Revision: 20220412
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC6984456
DOI: 10.3389/fphar.2019.01552
PMID: 32038240
قاعدة البيانات: MEDLINE
الوصف
تدمد:1663-9812
DOI:10.3389/fphar.2019.01552